Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 2, 2008, Pages 284-290

  Penning van Beest, F J A ^a   Koerselman, J ^a   Herings, R M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic drugs; Anticoagulants; Bleeding; Coumarins; Daily practise; Drug interactions

Indexed keywords

ACENOCOUMAROL; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFRADINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; COUMARIN DERIVATIVE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; NEOMYCIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PENICILLIN V; PHENETICILLIN; PHENPROCOUMON; TETRACYCLINE; TRIMETHOPRIM;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG POTENTIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UTERUS BLEEDING;

EID: 38349134238     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02844.x     Document Type: Article

References (25)

1. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): Third edition -2005 update. Br J Haematol 2006; 132: 277-85.
2. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: Third edition. Br J Haematol 1998; 101: 374-87.
3. Bovill EG, Fung M, Cushman M. Vitamin K and oral anticoagulation: thought for food. Am J Med 2004; 116: 711-3.
4. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl. 1): 8S-21S.
5. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-44.
6. Penning-van Beest FJA, Koerselman J, Herings RMC. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci 2007; 29: 671-5.
7. Stockley IH. Drug Interactions, 6th edn. London: The Pharmaceutical Press, 2002.
8. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88: 705-10.
9. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005; 61: 439-44.
10. Herings RMC. PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands. Thesis. Utrecht: Utrecht University, 1993.
11. Catalan VS, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000; 3: 417-26.
12. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70.
13. Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. The Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw-Hill, 2001.
14. Kelly M, Moran J, Byrne S. Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: A case report. Am J Geriatr Pharmacother 2005; 3: 266-9.
15. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003; 37: 367-70.
16. Soto J, Sacristan JA, Alsar MJ, Fernandez-Viadero C, Verduga R. Probable acenocoumarol-amoxycillin interaction. Acta Haematol 1993; 90: 195-7.
17. Khan MA, Muzammil S, Musarrat J. Differential binding of tetracyclines with serum albumin and induced structural alterations in drug-bound protein. Int J Biol Macromol 2002; 30: 243-9.
18. Baciewicz AM, Bal BS. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med 2001; 161: 1231.
19. Caraco Y, Rubinow A. Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother 1992; 26: 1084-6.
20. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001a; 69: 451-7.
21. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001b; 86: 569-74.
22. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med 2005; 20: 653-6.
23. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24: 1668-74.
24. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002; 11: 569-76.
25. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: Warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-46.